STRUCTURE THERAPEUTICS INC. - AMERICAN DEPOSITARY

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

17 Dec 2024 15:01:00 By Nasdaq GlobeNewswire

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

15 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

13 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

13 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024 

31 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

17 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

27 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

26 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

08 Aug 2024 15:05:01 By Nasdaq GlobeNewswire

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares

07 Jun 2024 15:05:25 By Nasdaq GlobeNewswire

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

05 Jun 2024 18:53:55 By Nasdaq GlobeNewswire

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

03 Jun 2024 15:09:23 By Nasdaq GlobeNewswire

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

03 Jun 2024 06:30:00 By Nasdaq GlobeNewswire

Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

09 May 2024 15:05:00 By Nasdaq GlobeNewswire

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

08 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

08 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

18 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

14 Nov 2023 15:10:00 By Nasdaq GlobeNewswire

Structure Therapeutics Announces $300 Million Private Placement Equity Financing

29 Sep 2023 06:32:00 By Nasdaq GlobeNewswire

Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update

29 Sep 2023 06:30:00 By Nasdaq GlobeNewswire